Proactive Investors - Run By Investors For Investors

AusCann Group signs a medical cannabis deal with Columbia based Khiron Life Sciences

The companies will collaborate on activities to develop cannabinoid medicines as a medical option in Chile.
medical cannabis
Khiron is listed on the TSX Venture Exchange in Canada

AusCann Group Holdings Ltd’s (ASX:AC8) Chilean joint venture DayaCann has signed a memorandum of understanding (MoU) with Columbian medical cannabis company Khiron Life Sciences Corp (CVE:KHRN).

Khiron has its core operations in Colombia and aims to address the unmet medical needs in a market of over 620 million people in Latin America.

The MoU contemplates a method of collaboration through which new alternatives of medical cannabis are offered to patients in Chile.

To achieve this, the parties will engage in cultivation, manufacturing, pedagogical, scientific and other activities that present cannabinoid medicines as a viable medical option.

READ: AusCann Group commences trading in the US increasing global exposure

As part of the agreement, Khiron will provide funds to support the development of these activities.

Under the MoU, DayaCann will provide cultivation and manufacturing services to Khiron.

AusCann and Fundación Daya formed DayaCann in 2016 with the aim of becoming Latin America’s leading medicinal cannabis group.

It is worth noting that DayaCann is the only company in Chile to hold a medical cannabis production licence.

 

DayaCann has already completed two harvests at its 30-hectare facility yielding a total of over 1000 kilograms of dried cannabis flower.

A portion of this cannabis is being used by Chilean pharmaceutical manufacturing group, Knop Laboratories, to create medical cannabis products available to Chilean patients via a special access scheme.

READ: Auscann Group makes steady progress towards production of cannabinoid medicines

AusCann managing director Elaine Darby said: “We look forward to working with Khiron through our joint venture DayaCann.

“To be supplying them high quality cannabinoid medicines and working together on addressing the needs of the Latin American market.

“The MoU will not only expand DayaCann’s presence in Chile, but also give DayaCann wider access to the Latin American market.”

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full AC8 profile View Profile

AusCann Group Holdings Ltd Timeline

Related Articles

medicinal cannabis concept
January 31 2019
Zelda has released its December quarterly report confirming multiple trials are on track.
cannabis plant
March 09 2019
The Vancouver company's recent move into Jamaica, which covers the acquisition of 145 acres of cultivation property, will pave the way for the development of cannabis brands for the island nation
1541165310_canadian-flag-1.jpg
November 03 2018
Back Home Medical Cannabis Corp has agreed on a 24,000-kilogram three-year production and supply agreement

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use